首页> 外文期刊>Cancer control : >Management of encapsulating peritoneal sclerosis: a guideline on optimal and uniformtreatment
【24h】

Management of encapsulating peritoneal sclerosis: a guideline on optimal and uniformtreatment

机译:包膜性腹膜硬化的处理:最佳和统一治疗指南

获取原文
           

摘要

Encapsulating peritoneal sclerosis (EPS) represents a rare complication of long-term peritoneal dialysis (PD). It is characterised by diffuse peritoneal membrane fibrosis, progressive intestinal encapsulation and the clinical spectrum of intestinal obstruction. The pathogenesis is as yet not well understood but includes inflammation, angiogenesis and fibrosis. The current diagnosis of EPS lacks specificity and relies on clinical, radiographic or macroscopic evaluation. There is no general agreement on managing EPS although accumulating clinical data suggest drug treatment (steroids, tamoxifen), surgery (enterolysis) or a combination of both. Here, we provide a short overview on the current knowledge of EPS, with a focus on treatment. Moreover, we present a diagnostic and a therapeutic algorithm for EPS based on the best available published data and our combined experience.
机译:封装性腹膜硬化症(EPS)代表了长期腹膜透析(PD)的罕见并发症。其特点是弥漫性腹膜膜纤维化,进行性肠包膜和肠梗阻的临床表现。发病机理尚不十分清楚,但包括炎症,血管生成和纤维化。 EPS的当前诊断缺乏特异性,并且依赖于临床,放射学或宏观评估。尽管累积的临床数据提示药物治疗(类固醇,他莫昔芬),手术(肠溶)或两者结合,但在管理EPS方面尚无普遍共识。在这里,我们简要介绍了EPS的当前知识,重点是治疗。此外,我们根据可获得的最佳公开数据和我们的综合经验,提出了EPS的诊断和治疗算法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号